Handelen Agile Therapeutics, Inc. - AGRX CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Spread | 0.3364 | ||||||||
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
Min. verhandelde hoeveelheid | 1 | ||||||||
Valuta | USD | ||||||||
Marge | 20% | ||||||||
Effectenbeurs | United States of America | ||||||||
Handelscommissie | 0% |
*Information provided by Capital.com
Agile Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 3.633 |
Open* | 3.6413 |
1-Jaarlijkse Verandering* | 169.73% |
Dagelijks bereik* | 3.5519 - 3.6512 |
52 wekelijks bereik | 3.36-141.00 |
Weekgemiddelde volume (10 dagen) | 37.98K |
Gemiddeld volume (3 maanden) | 581.43K |
Marktkapitalisatie | 10.89M |
P/E Ratio | -100.00K |
Uitstaande Aandelen | 2.93M |
Omzet | 12.94M |
EPS | -49.21 |
Dividend (opbrengst %) | N/A |
Beta | 1.14 |
Volgende inkomsten datum | Aug 9, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 3.6218 | -0.0194 | -0.53% | 3.6412 | 3.7197 | 3.5236 |
Jun 1, 2023 | 3.6330 | 0.0598 | 1.67% | 3.5732 | 3.6429 | 3.5729 |
May 31, 2023 | 3.5830 | 0.0610 | 1.73% | 3.5220 | 3.6621 | 3.4656 |
May 30, 2023 | 3.6136 | 0.0392 | 1.10% | 3.5744 | 3.7017 | 3.5633 |
May 26, 2023 | 3.5451 | 0.0694 | 2.00% | 3.4757 | 3.5745 | 3.4756 |
May 25, 2023 | 3.5352 | -0.2915 | -7.62% | 3.8267 | 3.8367 | 3.4064 |
May 24, 2023 | 3.8282 | 0.3852 | 11.19% | 3.4430 | 3.8667 | 3.4430 |
May 23, 2023 | 3.9058 | 0.4990 | 14.65% | 3.4068 | 4.1511 | 3.3862 |
May 22, 2023 | 3.6039 | -0.2310 | -6.02% | 3.8349 | 3.8578 | 3.2311 |
May 19, 2023 | 3.8571 | -0.1963 | -4.84% | 4.0534 | 4.1013 | 3.8074 |
May 18, 2023 | 4.0530 | -0.1250 | -2.99% | 4.1780 | 4.2280 | 3.9127 |
May 17, 2023 | 4.2682 | -0.0228 | -0.53% | 4.2910 | 4.3107 | 3.5907 |
May 16, 2023 | 4.3071 | -0.3301 | -7.12% | 4.6372 | 4.6386 | 4.2775 |
May 15, 2023 | 4.6298 | -0.2047 | -4.23% | 4.8345 | 4.8643 | 4.6192 |
May 12, 2023 | 4.8342 | -1.0242 | -17.48% | 5.8584 | 5.8584 | 4.7643 |
May 11, 2023 | 5.5083 | -0.1999 | -3.50% | 5.7082 | 5.8107 | 5.0069 |
May 10, 2023 | 5.7129 | -0.2890 | -4.82% | 6.0019 | 6.2693 | 5.6647 |
May 9, 2023 | 5.9766 | -0.2196 | -3.54% | 6.1962 | 6.3485 | 5.9751 |
May 8, 2023 | 6.2118 | 0.4026 | 6.93% | 5.8092 | 6.2708 | 5.8092 |
May 5, 2023 | 5.7226 | -0.0844 | -1.45% | 5.8070 | 5.8598 | 5.6336 |
Agile Therapeutics, Inc. Events
Tijd (UTC) (UTC) | Land | Evenement |
---|---|---|
Thursday, June 8, 2023 | ||
Tijd (UTC) (UTC) 13:00 | Land US
| Evenement Agile Therapeutics Inc Annual Shareholders Meeting Agile Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Friday, June 9, 2023 | ||
Tijd (UTC) (UTC) 13:00 | Land US
| Evenement Agile Therapeutics Inc Annual Shareholders Meeting Agile Therapeutics Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, August 9, 2023 | ||
Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Agile Therapeutics Inc Earnings Release Q2 2023 Agile Therapeutics Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
Tijd (UTC) (UTC) 21:00 | Land US
| Evenement Q3 2023 Agile Therapeutics Inc Earnings Release Q3 2023 Agile Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totale inkomsten | 10.884 | 4.101 | 0.749 | 0 | 0 |
Totale bedrijfskosten | 63.44 | 75.106 | 49.802 | 18.858 | 19.535 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 42.229 | 58.142 | 36.02 | 9 | 8.739 |
Onderzoek & Ontwikkeling | 3.253 | 6.246 | 13.5 | 9.858 | 9.777 |
Bedrijfsresultaat | -52.556 | -71.005 | -49.053 | -18.858 | -19.535 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 22.469 | -0.062 | -2.8 | 0.252 | -0.721 |
Netto inkomen voor belastingen | -30.087 | -71.067 | -51.853 | -18.606 | -20.256 |
Netto inkomen na belastingen | -25.412 | -71.067 | -51.853 | -18.606 | -19.779 |
Netto inkomen voor extra. Posten | -25.412 | -71.067 | -51.853 | -18.606 | -19.779 |
Netto inkomen | -25.412 | -71.067 | -51.853 | -18.606 | -19.779 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -25.412 | -71.067 | -51.853 | -18.606 | -19.779 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -25.412 | -71.067 | -51.853 | -18.606 | -19.779 |
Verwaterd Netto Inkomen | -25.412 | -71.067 | -51.853 | -18.606 | -19.779 |
Verwaterd Gewogen Gemiddelde Aandelen | 0.43222 | 0.04854 | 0.04234 | 0.02472 | 0.01716 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -58.7943 | -1464.2 | -1224.64 | -752.784 | -1152.76 |
Verwaterde Genormaliseerde Winst per Aandeel | -42.0683 | -1464.2 | -1224.64 | -752.784 | -1114.16 |
Ongebruikelijke uitgaven (inkomsten) | 11.122 | 0 | 0 | 1.019 | |
Inkomsten | 10.884 | 4.101 | 0.749 | ||
Kosten van opbrengsten, totaal | 6.836 | 10.718 | 0.282 | ||
Brutowinst | 4.048 | -6.617 | 0.467 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totale inkomsten | 3.813 | 3.996 | 3.002 | 2.126 | 1.761 |
Inkomsten | 3.813 | 3.996 | 3.002 | 2.126 | 1.761 |
Kosten van opbrengsten, totaal | 2.003 | 1.653 | 1.425 | 2.231 | 1.527 |
Brutowinst | 1.81 | 2.343 | 1.577 | -0.105 | 0.234 |
Totale bedrijfskosten | 10.521 | 10.874 | 21.71 | 13.524 | 17.334 |
Verkoop/Algemeen/Admin. Uitgaven, Totaal | 7.755 | 8.869 | 8.375 | 10.437 | 14.55 |
Onderzoek & Ontwikkeling | 0.763 | 0.352 | 0.788 | 0.856 | 1.257 |
Bedrijfsresultaat | -6.708 | -6.878 | -18.708 | -11.398 | -15.573 |
Renteopbrengsten (-uitgaven), netto Niet-operationeel | 1.318 | 25.118 | 12.778 | 6.23 | 0.513 |
Netto inkomen voor belastingen | -5.39 | 18.24 | -5.93 | -5.168 | -15.06 |
Netto inkomen na belastingen | -5.39 | 18.24 | -5.93 | -5.168 | -10.385 |
Netto inkomen voor extra. Posten | -5.39 | 18.24 | -5.93 | -5.168 | -10.385 |
Netto inkomen | -5.39 | 18.24 | -5.93 | -5.168 | -10.385 |
Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -5.39 | 18.24 | -5.93 | -5.168 | -10.385 |
Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -5.39 | 18.24 | -5.93 | -5.168 | -10.385 |
Verwaterd Netto Inkomen | -5.39 | 18.24 | -5.93 | -5.168 | -10.385 |
Verwaterd Gewogen Gemiddelde Aandelen | 0.91204 | 0.82896 | 0.73996 | 0.0902 | 0.0623 |
Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -5.9098 | 22.0034 | -8.01398 | -57.2921 | -166.682 |
Verwaterde Genormaliseerde Winst per Aandeel | -5.9098 | 22.0034 | 7.01663 | -57.2921 | -166.682 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Ongebruikelijke uitgaven (inkomsten) | 0 | 11.122 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Totaal vlottende activa | 11.358 | 23.925 | 56.785 | 35.319 | 8.458 |
Geldmiddelen en kortetermijnbeleggingen | 5.246 | 19.143 | 54.471 | 34.479 | 7.851 |
Geldmiddelen & Equivalenten | 5.246 | 19.143 | 14.463 | 34.479 | 7.851 |
Prepaid Expenses | 0.628 | 0.775 | 0.68 | 0.656 | 0.484 |
Other Current Assets, Total | 0.775 | 1.508 | 0.769 | 0.184 | 0.123 |
Total Assets | 14.242 | 39.333 | 73.062 | 49.54 | 22.392 |
Property/Plant/Equipment, Total - Net | 0.872 | 13.396 | 14.381 | 14.221 | 13.916 |
Property/Plant/Equipment, Total - Gross | 0.948 | 15.546 | 14.466 | 14.608 | 14.285 |
Accumulated Depreciation, Total | -0.076 | -2.15 | -0.085 | -0.387 | -0.369 |
Other Long Term Assets, Total | 2.012 | 2.012 | 1.896 | 0.018 | |
Total Current Liabilities | 13.387 | 29.278 | 7.353 | 3.795 | 2.218 |
Accounts Payable | 7.734 | 8.707 | 3.867 | 1.819 | 0.875 |
Accrued Expenses | 4.227 | 3.738 | 3.486 | 1.976 | 1.343 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.426 | 16.833 | 0 | ||
Other Current Liabilities, Total | 0 | ||||
Total Liabilities | 19.787 | 30.062 | 23.734 | 3.795 | 2.218 |
Total Long Term Debt | 0 | 0 | 16.381 | 0 | 0 |
Long Term Debt | 0 | 16.381 | 0 | ||
Total Equity | -5.545 | 9.271 | 49.328 | 45.745 | 20.174 |
Common Stock | 0.004 | 0.012 | 0.009 | 0.007 | 0.003 |
Additional Paid-In Capital | 403.153 | 396.376 | 361.539 | 306.108 | 261.722 |
Retained Earnings (Accumulated Deficit) | -408.702 | -387.117 | -312.223 | -260.37 | -241.551 |
Total Liabilities & Shareholders’ Equity | 14.242 | 39.333 | 73.062 | 49.54 | 22.392 |
Total Common Shares Outstanding | 0.8594 | 0.0607 | 0.04378 | 0.03491 | 0.01719 |
Korte Termijn Investeringen | 0 | 40.008 | |||
Totale Vorderingen, Netto | 3.377 | 1.533 | 0.865 | ||
Accounts Receivable - Trade, Net | 3.377 | 1.533 | 0.865 | ||
Other Equity, Total | 0 | 0.003 | |||
Total Inventory | 1.332 | 0.966 | |||
Other Liabilities, Total | 6.4 | 0.784 | |||
Total Preferred Shares Outstanding | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Totaal vlottende activa | 10.906 | 11.358 | 15.487 | 18.47 | 14.352 |
Geldmiddelen en kortetermijnbeleggingen | 4.429 | 5.246 | 6.145 | 13.027 | 3.743 |
Geldmiddelen & Equivalenten | 4.429 | 5.246 | 6.145 | 13.027 | 3.743 |
Korte Termijn Investeringen | |||||
Totale Vorderingen, Netto | 3.123 | 3.377 | 3.711 | 2.087 | 6.34 |
Accounts Receivable - Trade, Net | 3.123 | 3.377 | 3.711 | 2.087 | 1.665 |
Total Inventory | 2.211 | 1.332 | 1.797 | 2.34 | 2.693 |
Prepaid Expenses | 0.55 | 0.628 | 1.033 | 0.199 | 0.608 |
Other Current Assets, Total | 0.593 | 0.775 | 2.801 | 0.817 | 0.968 |
Total Assets | 13.697 | 14.242 | 18.463 | 32.831 | 29.299 |
Property/Plant/Equipment, Total - Net | 0.779 | 0.872 | 0.964 | 12.349 | 12.935 |
Other Long Term Assets, Total | 2.012 | 2.012 | 2.012 | 2.012 | 2.012 |
Total Current Liabilities | 18.506 | 13.387 | 11.653 | 28.782 | 25.848 |
Accounts Payable | 10.358 | 7.734 | 4.906 | 12.036 | 9.537 |
Accrued Expenses | 6.64 | 4.227 | 5.429 | 4.116 | 4.059 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.508 | 1.426 | 1.318 | 12.63 | 12.252 |
Total Liabilities | 23.131 | 19.787 | 12.203 | 29.412 | 26.556 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Long Term Debt | 0 | 0 | 0 | ||
Other Liabilities, Total | 4.625 | 6.4 | 0.55 | 0.63 | 0.708 |
Total Equity | -9.434 | -5.545 | 6.26 | 3.419 | 2.743 |
Common Stock | 0.00009 | 0.004 | 0.004 | 0.001 | 0.00034 |
Additional Paid-In Capital | 404.658 | 403.153 | 437.027 | 414.523 | 400.742 |
Retained Earnings (Accumulated Deficit) | -414.092 | -408.702 | -430.771 | -411.105 | -398.886 |
Other Equity, Total | -0.00009 | -0.00034 | |||
Total Liabilities & Shareholders’ Equity | 13.697 | 14.242 | 18.463 | 32.831 | 29.299 |
Total Common Shares Outstanding | 0.9321 | 0.8594 | 0.78054 | 0.2472 | 0.06731 |
Redeemable Preferred Stock | 0.887 | ||||
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0.00243 |
- Jaarlijks
- Per kwartaal
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Netto-inkomen/Beginsaldo | -25.412 | -74.894 | -51.853 | -18.606 | -19.779 |
Geldmiddelen uit Operationele Activiteiten | -35.947 | -65.202 | -47.311 | -15.689 | -16.895 |
Geldmiddelen uit Operationele Activiteiten | 1.534 | 2.223 | 0.276 | 0.163 | 0.023 |
Niet-Geldelijke Posten | -9.936 | 10.322 | 4.159 | 1.762 | 3.883 |
Cash Taxes Paid | 0 | 0 | 0 | ||
Contant Betaalde Rente | 1.162 | 2.383 | 2.099 | 0 | 1.37 |
Veranderingen in het Operationeel Kapitaal | -2.133 | -2.853 | 0.107 | 0.992 | -1.022 |
Geldmiddelen uit Investeringsactiviteiten | -0.133 | 39.46 | -40.69 | -0.098 | -0.318 |
Kapitaaluitgaven | -0.133 | -0.269 | -0.353 | -0.098 | -0.318 |
Geldmiddelen uit Financieringsactiviteiten | 22.183 | 30.422 | 67.985 | 42.415 | -10.888 |
Financiering van Cash Flow Posten | 0 | -1.059 | 0 | ||
Uitgifte (Aflossing) van aandelen, netto | 39.558 | 30.422 | 49.044 | 42.415 | 0 |
Uitgifte (Aflossing) van Schulden, Netto | -17.375 | 0 | 20 | 0 | -10.888 |
Nettowijziging in Geldmiddelen | -13.897 | 4.68 | -20.016 | 26.628 | -28.101 |
Overige Cash Flow investeringsposten, Totaal | 0 | 39.729 | -40.337 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -5.39 | -25.412 | -43.652 | -23.988 | -11.769 |
Cash From Operating Activities | -1.595 | -35.947 | -34.388 | -17.685 | -14.751 |
Cash From Operating Activities | 0.093 | 1.534 | 1.443 | 1.181 | 0.588 |
Non-Cash Items | -0.882 | -9.936 | 14.726 | 2.23 | -3.492 |
Cash Interest Paid | 0.094 | 1.162 | 1.078 | 0.898 | 0.452 |
Changes in Working Capital | 4.584 | -2.133 | -6.905 | 2.892 | -0.078 |
Cash From Investing Activities | 0 | -0.133 | -0.133 | -0.133 | -0.126 |
Capital Expenditures | 0 | -0.133 | -0.133 | -0.133 | -0.126 |
Other Investing Cash Flow Items, Total | 0 | 0 | 0 | 0 | |
Cash From Financing Activities | 0.778 | 22.183 | 21.523 | 11.702 | -0.523 |
Financing Cash Flow Items | |||||
Issuance (Retirement) of Stock, Net | 1.003 | 39.558 | 38.673 | 16.702 | 4.477 |
Issuance (Retirement) of Debt, Net | -0.225 | -17.375 | -17.15 | -5 | -5 |
Net Change in Cash | -0.817 | -13.897 | -12.998 | -6.116 | -15.4 |
Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
---|---|---|---|---|---|---|
LPL Financial LLC | Investment Advisor | 0.281 | 8230 | 0 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.207 | 6062 | -5 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.1627 | 4765 | -12 | 2023-03-31 | LOW |
Virtu Americas LLC | Research Firm | 0.0812 | 2378 | -476 | 2023-03-31 | HIGH |
Investor AB | Private Equity | 0.0599 | 1755 | 0 | 2023-03-31 | LOW |
Advisory Services Network, LLC | Investment Advisor | 0.0557 | 1630 | 0 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 0.0525 | 1537 | 0 | 2023-03-31 | LOW |
Altomari (Alfred) | Individual Investor | 0.0439 | 1286 | -1 | 2023-04-24 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0363 | 1063 | 0 | 2023-03-31 | LOW |
Millennium Management LLC | Hedge Fund | 0.0311 | 911 | -245 | 2023-03-31 | HIGH |
Baader Bank AG | Investment Advisor/Hedge Fund | 0.0215 | 629 | 629 | 2023-03-31 | MED |
Two Sigma Investments, LP | Hedge Fund | 0.0204 | 598 | 125 | 2023-03-31 | HIGH |
HRT Financial LP | Investment Advisor | 0.0085 | 249 | 249 | 2023-03-31 | LOW |
Confluence Financial Partners | Investment Advisor | 0.0077 | 225 | 225 | 2023-03-31 | MED |
Citi Investment Research (US) | Research Firm | 0.0062 | 182 | -2 | 2023-03-31 | LOW |
First Midwest Trust Company | Bank and Trust | 0.0027 | 80 | -88 | 2021-12-31 | |
Morgan Stanley & Co. LLC | Research Firm | 0.0016 | 46 | -1 | 2023-03-31 | MED |
BG Fund Management Luxembourg S.A. | Investment Advisor | 0.0015 | 43 | 0 | 2023-02-28 | MED |
Shetty (Ajit S) | Individual Investor | 0.0011 | 31 | 0 | 2023-04-24 | LOW |
Gilmore (Geoffrey P) | Individual Investor | 0.001 | 30 | -11 | 2023-04-24 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Agile Therapeutics, Inc. Company profile
Over Agile Therapeutics, Inc.
Agile Therapeutics, Inc. is een bedrijf actief in de gezondheidszorg voor vrouwen. Het goedgekeurde product van de onderneming, Twirla, ook bekend als AG200-15, is een anticonceptiepleister die één keer per week op voorschrift wordt aangebracht. Twirla maakt gebruik van zijn transdermale pleistertechnologie, Skinfusion genaamd. Skinfusion is ontworpen om medicijnafgifte via de huid mogelijk te maken en tegelijkertijd de hechting van de patch en het draagcomfort voor de patiënt te optimaliseren, wat de therapietrouw kan bevorderen. De productpijplijn bestaat uit twee soorten productkandidaten: Twirla lijnuitbreidingen en andere transdermale contraceptieve productkandidaten. Deze potentiële productkandidaten zijn ontworpen om tegemoet te komen aan de marktbehoeften aan bijkomende niet-dagelijkse contraceptieve opties. De uitbreidingen van de Twirla-lijn omvatten AG200-15 Extended Regimen (ER), AG200-15 SmP, AG200-15 ER SmP, en AG890, een P-only anticonceptieve patch.
Industry: | Bio Therapeutic Drugs |
500 College Road East
Suite 310
PRINCETON
NEW JERSEY 08540-6635
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen